Insider Trading April 16, 2026 08:01 PM

Slide Insurance COO Shannon Lucas Sells $340K in Stock as Company Reports Strong Q4

Transaction executed under a prearranged 10b5-1 plan; firm posts better-than-expected earnings and expands buyback authorization

By Jordan Park SLDE
Slide Insurance COO Shannon Lucas Sells $340K in Stock as Company Reports Strong Q4
SLDE

Shannon Lucas, president and COO of Slide Insurance Holdings Inc (SLDE), sold 18,874 shares on April 14, 2026 under a 10b5-1 plan, generating $340,486. The company recently reported robust fourth-quarter 2025 results, completed a $120 million buyback and authorized a new $125 million program, while several brokers maintained or raised ratings.

Key Points

  • Shannon Lucas sold 18,874 shares on April 14, 2026 under a 10b5-1 plan for $340,486 at a weighted average price of $18.04; trade prices ranged from $18.00 to $18.09.
  • After the sale Lucas holds 208,101 shares directly and 1,382,574 indirectly via Securus Risk Management, LLC; Lucas’s spouse indirectly holds 45,446,485 shares.
  • Slide Insurance reported strong Q4 2025 results with EPS of $1.23 versus $0.71 expected, revenue of $347 million (up from $238.5 million), completed a $120 million buyback and authorized a new $125 million program; several brokers maintained or raised positive ratings.

Shannon Lucas, who serves as president and chief operating officer of Slide Insurance Holdings Inc (NYSE: SLDE), disposed of 18,874 shares of the company’s common stock on April 14, 2026, according to a Form 4 filed with the Securities and Exchange Commission.

The shares were sold at a weighted average price of $18.04, producing total proceeds of $340,486. The reported per-share sale prices ranged from $18.00 to $18.09. Since that trade, Slide Insurance’s share price has climbed to $18.99, a 29% gain over the prior six months.

The disposition was carried out pursuant to a 10b5-1 trading arrangement that Lucas adopted on November 21, 2025. After the sale, Lucas is recorded as directly holding 208,101 shares and indirectly holding 1,382,574 shares through Securus Risk Management, LLC. The filing also notes that Lucas’s spouse indirectly holds 45,446,485 shares.


Company performance and capital allocation

Slide Insurance reported a strong fourth quarter for 2025, posting earnings per share of $1.23 versus consensus expectations of $0.71. Revenue for the quarter was $347 million, up from $238.5 million a year earlier. In addition to top-line and earnings beats, the company completed a $120 million stock buyback program and has authorized a new $125 million repurchase initiative.

Analysts have reacted to the company’s results and capital actions. Barclays reiterated an Overweight rating with a $29 price target. Texas Capital Securities initiated coverage with a Buy rating and a $25 price target. Keefe, Bruyette & Woods lifted its price target to $23 from $22 and maintained an Outperform rating, citing the strong fourth-quarter outcome.


Valuation signal

According to InvestingPro analysis cited in the filing, SLDE appears undervalued at current market levels. The platform provides additional ProTips and financial health metrics for the stock.

This reporting summarizes the regulatory filing and recent corporate disclosures. The transaction was executed under an established trading plan and occurred amid a period of notable company-level financial and capital allocation developments.

Risks

  • Insider selling occurred despite strong company results - this single transaction may create investor questions about insider timing or liquidity needs, potentially impacting investor sentiment in the insurance and financials sectors.
  • Reliance on analyst price targets and third-party platform valuations - references to InvestingPro’s view that SLDE is undervalued and to various price targets reflect external assessments that may change, affecting market expectations for the insurance sector.
  • Large indirect holdings by a spouse - the existence of substantial indirect holdings (45,446,485 shares) could introduce concentration-related governance or market liquidity considerations for shareholders and the broader financial markets.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026